drugset / Trial / NCT00543569

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

NCT00543569

Phase 2 Completed 323 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.

Timeline

Start
2008-02
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intravenous
Subject Tacrolimus Small molecule Oral
Comparator Basiliximab Monoclonal antibody 20 mg
Background Mycophenolate Mofetil Small molecule 750 mg Oral
Background Mycophenolate Mofetil Small molecule 1000 mg Oral

Indications

No indication recorded.